Bionano Genomics, Inc. (BNGO)

Every figure this model derived for BNGO, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PaymentsToAcquireOtherProductiveAssets 2025-12-31
cash 9,919,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 24,878,000 AssetsCurrent 2026-06-30
current liabilities 10,039,000 LiabilitiesCurrent 2026-06-30
equity 31,606,000 StockholdersEquity 2026-06-30
interest expense 1,353,000 InterestPaidNet 2026-06-30
ocf -20,480,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 30,176,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 3,507,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up BNGO on one particular measure came for.

RatioValue
cash operating margin-64.17
current ratio2.8
current ratio reported2.48
deferred revenue growth-1.72
dilution pct328.83
fcf margin-67.87
growth cv1.32
interest cover-23.79
operating margin-106.67
owner earnings margin-79.49
revenue growth10.03
revenue growth per share-74.34
roic-100.22
rpo growth-7.14
rule of 40-96.64
sbc pct revenue11.62

What to be careful about

What this model itself distrusts about BNGO's figures. Written by the derivation as it ran, not added afterwards.